- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05592925
Association Between Multiple Coagulation-related Factors and Lymph Node Metastasis in Patients With Gastric Cancer: A Retrospective Cohort Study (MA)
October 21, 2022 updated by: Feng Tian, Shandong Provincial Hospital
We initially selected a total of 1128 patients with primary gastric cancer who presented at Shandong Provincial Hospital between January 2018 and October 2022, and retrospectively collected their clinical and pathological data.
And retrospectively analyzed preoperative baseline characteristics, preoperative laboratory tests, and postoperative pathological results for these patients
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
516
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Feng Tian, Doctor
- Phone Number: 18866102886
- Email: tianfeng@sdu.edu.cn
Study Contact Backup
- Name: Changqing Jing, Doctor
- Phone Number: 15168888987
- Email: jingchangqing@sdfmu.edu.cn
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250021
- Recruiting
- Shandong Provincial Hospital
-
Contact:
- Feng Tian, Doctor
- Phone Number: 18866102886
- Email: tianfeng@sdu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
patients with primary gastric cancer
Description
Inclusion Criteria:
- patients with primary gastric malignant tumors,
- patients who underwent radical resection of gastric cancer,
- patients with a postoperative pathology of adenocarcinoma or signet ring cell carcinoma according to the WTO pathological classification,
Exclusion Criteria:
- patients who have distant metastases, such as liver or lung metastases, were found on preoperative ultrasound and computed tomography (CT) examinations,
- patients who have received preoperative neoadjuvant chemotherapy,
- patients who take anticoagulant drugs (such as aspirin) prior to surgery,
- patients who had any previous coagulation disorder.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
N0
gastric cancer patients with no lymph node metastasis
|
We retrospectively evaluated the relationship between lymph node metastasis and coagulation-related factors in 516 patients with T4a stage gastric cancer.
|
N+
gastric cancer patients with lymph node metastasis, including patients with N1, N2 and N3 stage cancer
|
We retrospectively evaluated the relationship between lymph node metastasis and coagulation-related factors in 516 patients with T4a stage gastric cancer.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Preoperative coagulation-related factors (MA values) of patients
Time Frame: Three years
|
MA values(mm).
Measure the data of preoperative MA values in 516 gastric cancer patients to see wether this indicator correlated with tumor stage in patients with gastric cancer.
|
Three years
|
Preoperative coagulation-related factors (platelet counts) of patients
Time Frame: Three years
|
Platelet counts(x10^9/L).
Measure the data of preoperative platelet counts in 516 gastric cancer patients to see wether this indicator correlated with tumor stage in patients with gastric cancer.
|
Three years
|
Preoperative coagulation-related factors (fibrinogen levels) of patients
Time Frame: Three years
|
Fibrinogen levels (g/L).
Measure the data of preoperative fibrinogen levels in 516 gastric cancer patients to see wether this indicator correlated with tumor stage in patients with gastric cancer.
|
Three years
|
Preoperative coagulation-related factors (D-dimer) of patients
Time Frame: Three years
|
D-dimer (mg/L).
Measure the data of preoperative D-dimer in 516 gastric cancer patients to see wether this indicator correlated with tumor stage in patients with gastric cancer.
|
Three years
|
Postoperative pathological results of tumor T stage.
Time Frame: Three years
|
Recording the postoperative pathological tumor T stage in 516 patients with gastric cancer.
|
Three years
|
Postoperative pathological results of tumor N stage.
Time Frame: Three years.
|
Recording the postoperative pathological tumor N stage in 516 patients with gastric cancer.
|
Three years.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Feng Tian, Doctor, Shandong Provincial Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2018
Primary Completion (Anticipated)
October 31, 2022
Study Completion (Anticipated)
October 31, 2022
Study Registration Dates
First Submitted
October 18, 2022
First Submitted That Met QC Criteria
October 21, 2022
First Posted (Actual)
October 25, 2022
Study Record Updates
Last Update Posted (Actual)
October 25, 2022
Last Update Submitted That Met QC Criteria
October 21, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FTian
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
After the article is published, the original data can be obtained by contacting the project leader.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer Stage
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterNot yet recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric... and other conditionsUnited States
-
University of ChicagoNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Esophageal Adenocarcinoma | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer | Stage IIB Gastric Cancer | Stage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal AdenocarcinomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on coagulation-related factors
-
Eio Biomedical Ltd.CompletedReduction of Postoperative AdhesionsLithuania
-
Central Hospital, Nancy, FranceCompletedRisk Factors | Necrotizing Enterocolitis of NewbornFrance
-
Second Affiliated Hospital, School of Medicine,...RecruitingInflammation | Cerebral Edema | Coagulation and Hemorrhagic DisordersChina
-
Peking University First HospitalNot yet recruitingBleeding | Pharmacodynamics | Apixaban | Pharmacogenomics | Biomarker | Ticagrelor | Rivaroxaban | Novel Oral Anticoagulants | NOACs | Dabigatran | Edoxaban | RNA ProfileChina
-
Pennington Biomedical Research CenterNational Institute of General Medical Sciences (NIGMS)Completed
-
University of CagliariUniversity of FoggiaCompletedOvarian EndometriomaItaly
-
University Hospital Inselspital, BerneWithdrawnKeloid | Hypertrophic Scars
-
Triemli HospitalUniversity of ZurichCompletedCoagulation Disorder, BloodSwitzerland
-
Dr. Servet AkarHacettepe University; Dokuz Eylul UniversityUnknown
-
University of PecsUnknownPerioperative/Postoperative Complications | Abdominal Aortic Aneurism | Abdominal Aortic Rupture | Surgical Blood Loss